Loading dose and efficacy of continuous or extended infusion of beta‐lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta‐analysis and meta‐regression analysis

What is known and objective The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performi...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacy and therapeutics Vol. 46; no. 2; pp. 424 - 432
Main Authors Wu, Chih‐Chien, Su, Yi‐Chia, Wu, Kuan‐Sheng, Wu, Tung‐Ho, Yang, Ching‐Shiang
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.04.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract What is known and objective The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performing a systematic review and meta‐analysis. Methods PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta‐analysis included 18 randomized controlled trials (RCTs) and 13 non‐RCTs. Results and discussion For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72–0.94) and 1.31 (95% CI: 1.15–1.49), respectively. Subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA. What is new and conclusion CEIs with loading‐dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients. Our subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). According to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.
AbstractList What is known and objective The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performing a systematic review and meta‐analysis. Methods PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta‐analysis included 18 randomized controlled trials (RCTs) and 13 non‐RCTs. Results and discussion For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72–0.94) and 1.31 (95% CI: 1.15–1.49), respectively. Subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA. What is new and conclusion CEIs with loading‐dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients. Our subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). According to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.
The role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta-lactams by performing a systematic review and meta-analysis. PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta-analysis included 18 randomized controlled trials (RCTs) and 13 non-RCTs. For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72-0.94) and 1.31 (95% CI: 1.15-1.49), respectively. Subgroup and meta-regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading-dose group (RR: 1.44, 95% CI: 1.22-1.69), which remained significant after adjustments for beta-lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20-1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA. CEIs with loading-dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients.
The role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta-lactams by performing a systematic review and meta-analysis.WHAT IS KNOWN AND OBJECTIVEThe role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta-lactams by performing a systematic review and meta-analysis.PubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta-analysis included 18 randomized controlled trials (RCTs) and 13 non-RCTs.METHODSPubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta-analysis included 18 randomized controlled trials (RCTs) and 13 non-RCTs.For CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72-0.94) and 1.31 (95% CI: 1.15-1.49), respectively. Subgroup and meta-regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading-dose group (RR: 1.44, 95% CI: 1.22-1.69), which remained significant after adjustments for beta-lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20-1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.RESULTS AND DISCUSSIONFor CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72-0.94) and 1.31 (95% CI: 1.15-1.49), respectively. Subgroup and meta-regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading-dose group (RR: 1.44, 95% CI: 1.22-1.69), which remained significant after adjustments for beta-lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20-1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.CEIs with loading-dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients.WHAT IS NEW AND CONCLUSIONCEIs with loading-dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients.
What is known and objectiveThe role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we aimed to compare the clinical efficacy of CEI versus intermittent administration (IA) of beta‐lactams by performing a systematic review and meta‐analysis.MethodsPubMed, the Cochrane Library and Embase were searched from inception until December 2018 for studies comparing clinical outcomes of CEI versus IA in critically ill patients. The meta‐analysis included 18 randomized controlled trials (RCTs) and 13 non‐RCTs.Results and discussionFor CEI versus IA, the summary relative risk (RR) for overall mortality and clinical cure was 0.82 (95% confidence interval [CI]: 0.72–0.94) and 1.31 (95% CI: 1.15–1.49), respectively. Subgroup and meta‐regression analyses of the loading dose revealed a significantly increased clinical cure rate in the loading‐dose group (RR: 1.44, 95% CI: 1.22–1.69), which remained significant after adjustments for beta‐lactam type, and association between clinical cure and loading dose for clinical cure (RR: 1.47, 95% CI: 1.20–1.80; p = .001). Subgroup analysis of administration type indicated that both groups had low mortality and high clinical cure rates; however, the heterogeneity analysis did not support an association across continuous infusion and extended infusion groups. Subgroup analysis of the Acute Physiology and Chronic Health Evaluation (APACHE) score was conducted; according to APACHE scores ≥ 16, overall mortality and clinical cure significantly differed between CEI and IA.What is new and conclusionCEIs with loading‐dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients.
Author Wu, Chih‐Chien
Wu, Tung‐Ho
Wu, Kuan‐Sheng
Yang, Ching‐Shiang
Su, Yi‐Chia
Author_xml – sequence: 1
  givenname: Chih‐Chien
  orcidid: 0000-0001-5791-4047
  surname: Wu
  fullname: Wu, Chih‐Chien
  organization: National Yang‐Ming University
– sequence: 2
  givenname: Yi‐Chia
  orcidid: 0000-0002-9544-1153
  surname: Su
  fullname: Su, Yi‐Chia
  email: s19101080@gm.ym.edu.tw
  organization: National Cheng‐Kung University
– sequence: 3
  givenname: Kuan‐Sheng
  surname: Wu
  fullname: Wu, Kuan‐Sheng
  organization: Kaohsiung Veterans General Hospital
– sequence: 4
  givenname: Tung‐Ho
  surname: Wu
  fullname: Wu, Tung‐Ho
  organization: Kaohsiung Veterans General Hospital
– sequence: 5
  givenname: Ching‐Shiang
  surname: Yang
  fullname: Yang, Ching‐Shiang
  email: csyang429@vghks.gov.tw
  organization: Kaohsiung Veterans General Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33135261$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAQxy1URLeFCw-ALHFBSCn-SJwst2oFBbQSHMo58sdk8Sqxg-2o3RuPwNtx50nq3exeKoQvY838_jPj8VygM-cdIPSSkiuaz7utHtMV5ZzQJ2hBuagKVlNyhhaEiWVR1qw-Rxcxbgkhomb8GTrnnPKKCbpAf9ZeGus22PgIWDqDoeuslnqHfYe1d8m6yU8R-4DhPoEzYLB13RStd3tEQZJ_f_3upU5yiFkxjDJk5s6mHxlMEAabsi5haQbrbExBpr3WOjzmW47EGdbBply5x7bvHcQI8T2-xnFSm-CnEQ9zIelkv4s2Hno9-gJsQhbss57Cz9HTTvYRXhztJfr-8cPt6lOx_nrzeXW9LjSvalpwBoo2SjdcMsZVQ0tV6-WSAm2YKjuohKpzDEh-djaipAZUpZRQpikN7fglejPnHYP_OUFM7WCjhr6XDvLYWlZWoqkEJyKjrx-hWz-F3G-mKkKbmrMly9SrIzWpAUw7BjvIsGtPX5YBMgM6-BgDdK226TDSPFnbt5S0-61o91vRHrYiS94-kpyy_hOmM3xne9j9h2y_rL7dzpoHZUPRRw
CitedBy_id crossref_primary_10_1186_s13613_024_01263_9
crossref_primary_10_1155_2024_9757792
crossref_primary_10_3390_antibiotics12030577
crossref_primary_10_3390_antibiotics12111581
crossref_primary_10_1016_j_iccn_2024_103786
crossref_primary_10_1080_14787210_2023_2184347
crossref_primary_10_1080_17425255_2022_2056012
crossref_primary_10_1016_j_jiac_2023_05_008
crossref_primary_10_3389_fvets_2021_770202
crossref_primary_10_1093_ofid_ofad305
crossref_primary_10_1093_jac_dkad215
crossref_primary_10_1097_CCE_0000000000000823
crossref_primary_10_1556_650_2024_33001
crossref_primary_10_1016_j_jinf_2023_06_023
crossref_primary_10_1007_s40262_023_01230_w
Cites_doi 10.1186/cc11405
10.1097/MCC.0b013e3283021b3a
10.5414/CPP43360
10.1177/0885066618784264
10.1007/BF02016564
10.1007/s10096-016-2819-1
10.1164/rccm.201601-0024OC
10.1164/rccm.201505-0857OC
10.1093/jac/dkl478
10.1111/j.1365-2125.2000.00179.x
10.1016/S0924-8579(01)00329-6
10.1128/AAC.01318-06
10.1007/s00134-015-4188-0
10.1086/516284
10.1016/j.ijantimicag.2006.02.020
10.1093/cid/cis856
10.1007/s00134-017-4683-6
10.1086/510590
10.1093/cid/ciu027
10.1186/1471-2288-14-135
10.1016/j.ijantimicag.2014.05.011
10.1093/jac/dkq516
10.1016/j.ijantimicag.2009.10.008
10.1093/cid/ciu402
10.1345/aph.1G467
10.1016/j.ijantimicag.2008.09.012
10.1177/0885066617708756
10.1128/AAC.02759-14
10.1016/j.clinthera.2007.11.003
10.1016/j.clinthera.2012.11.005
10.1177/0962280216669183
10.1345/aph.1S032
10.1093/jac/dkv288
10.4103/0366-6999.205859
10.1002/phar.1875
10.1371/journal.pone.0049845
10.1007/s40262-020-00919-6
10.1002/phar.1310
ContentType Journal Article
Copyright 2020 John Wiley & Sons Ltd
2020 John Wiley & Sons Ltd.
Copyright © 2021 John Wiley & Sons Ltd
Copyright_xml – notice: 2020 John Wiley & Sons Ltd
– notice: 2020 John Wiley & Sons Ltd.
– notice: Copyright © 2021 John Wiley & Sons Ltd
DBID AAYXX
CITATION
NPM
7T5
7TM
7TO
H94
K9.
M7N
7X8
DOI 10.1111/jcpt.13301
DatabaseName CrossRef
PubMed
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2710
EndPage 432
ExternalDocumentID 33135261
10_1111_jcpt_13301
JCPT13301
Genre article
Journal Article
GrantInformation_xml – fundername: Kaohsiung Veterans General Hospital
  funderid: VGHKS108‐58
– fundername: Kaohsiung Veterans General Hospital
  grantid: VGHKS108-58
GroupedDBID ---
.3N
.GA
.Y3
04C
05W
0R~
10A
1CY
1OB
1OC
24P
29K
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6PF
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
8FI
8FJ
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAJEY
AAKAS
AANHP
AAONW
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABPVW
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCMX
ACCZN
ACFBH
ACGFO
ACGFS
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOJX
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEGXH
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFEBI
AFGKR
AFKRA
AFPWT
AFRAH
AFZJQ
AHEFC
AHMBA
AIACR
AIAGR
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BENPR
BFHJK
BHBCM
BMSDO
BMXJE
BROTX
BRXPI
BY8
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
D-I
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
ECF
ECT
ECV
EIHBH
EJD
EMB
EMK
EMOBN
ENC
ENX
EPT
ESX
EX3
F00
F5P
FEDTE
FUBAC
FYUFA
FZ0
G-S
G.N
GODZA
GWYGA
H.X
HF~
HMCUK
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PIMPY
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RHX
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
UKHRP
V8K
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQ9
WQJ
WUP
WVDHM
WXI
WXSBR
XG1
YCJ
YFH
YOC
YUY
ZGI
ZZTAW
~IA
~WT
AAFWJ
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
NPM
7T5
7TM
7TO
H94
K9.
M7N
7X8
ID FETCH-LOGICAL-c3571-32eb18bc83a223b814b7c991e182b4fe56b783ae0ded3ae641deb5bb6bd84d1f3
IEDL.DBID DR2
ISSN 0269-4727
1365-2710
IngestDate Tue Aug 05 09:30:28 EDT 2025
Wed Aug 13 09:47:27 EDT 2025
Thu Apr 03 07:05:00 EDT 2025
Thu Apr 24 23:03:56 EDT 2025
Tue Jul 01 03:53:15 EDT 2025
Wed Jan 22 16:29:49 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords pharmacokinetics
loading dose
antibiotics
infectious diseases
Language English
License 2020 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3571-32eb18bc83a223b814b7c991e182b4fe56b783ae0ded3ae641deb5bb6bd84d1f3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-5791-4047
0000-0002-9544-1153
PMID 33135261
PQID 2501873292
PQPubID 37505
PageCount 9
ParticipantIDs proquest_miscellaneous_2456856306
proquest_journals_2501873292
pubmed_primary_33135261
crossref_citationtrail_10_1111_jcpt_13301
crossref_primary_10_1111_jcpt_13301
wiley_primary_10_1111_jcpt_13301_JCPT13301
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2021
2021-04-00
2021-Apr
20210401
PublicationDateYYYYMMDD 2021-04-01
PublicationDate_xml – month: 04
  year: 2021
  text: April 2021
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Journal of clinical pharmacy and therapeutics
PublicationTitleAlternate J Clin Pharm Ther
PublicationYear 2021
Publisher John Wiley & Sons, Inc
Publisher_xml – name: John Wiley & Sons, Inc
References 1998; 26
2013; 47
2010; 35
1983; 2
2017; 43
1999; 47
2008; 14
2000; 50
2014; 26
2020; 59
2005; 43
2020; 35
2016; 71
2017; 130
2012; 16
2007; 51
2011; 39
2012; 34
2018; 27
2014; 44
2007; 59
2007; 29
2009; 33
2015; 192
2014; 80
2006; 40
2017; 37
2013; 33
2017; 36
2013; 56
2006; 28
2016; 42
2014; 59
2014; 58
2014; 14
2011; 66
2001; 17
2012; 7
2018; 33
2007; 44
2016; 194
Wang Z (e_1_2_6_22_1) 2014; 26
e_1_2_6_32_1
e_1_2_6_10_1
e_1_2_6_30_1
Georges B (e_1_2_6_37_1) 1999; 47
Dhaese S (e_1_2_6_43_1) 2020; 59
Lipš M (e_1_2_6_31_1) 2014; 44
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_34_1
De Waele J (e_1_2_6_38_1) 2014; 80
e_1_2_6_12_1
e_1_2_6_33_1
Georges B (e_1_2_6_17_1) 2005; 43
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_15_1
e_1_2_6_16_1
e_1_2_6_42_1
e_1_2_6_21_1
e_1_2_6_20_1
e_1_2_6_41_1
Abdul‐Aziz MH (e_1_2_6_8_1) 2016; 71
Rhodes NJ (e_1_2_6_40_1) 2014; 59
Lagast H (e_1_2_6_29_1) 1983; 2
e_1_2_6_9_1
Arnold H (e_1_2_6_11_1) 2011; 39
Gonçalves‐Pereira J (e_1_2_6_28_1) 2012; 7
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
Lorente L (e_1_2_6_19_1) 2007; 29
e_1_2_6_27_1
e_1_2_6_26_1
References_xml – volume: 39
  start-page: 10
  year: 2011
  article-title: Prolonged vs. intermittent infusion of meropenem, piperacillin‐tazobactam, and cefepime for the treatment of life threatening gram‐negative infections in the intensive care unit
  publication-title: Crit Care Med
– volume: 37
  start-page: 109
  issue: 1
  year: 2017
  end-page: 119
  article-title: Clinical outcomes of extended versus intermittent infusion of piperacillin/tazobactam in critically ill patients: A prospective clinical trial
  publication-title: Pharmacotherapy
– volume: 34
  start-page: 2297
  issue: 12
  year: 2012
  end-page: 2300
  article-title: Outcomes of extended‐infusion piperacillin‐tazobactam: a retrospective analysis of critically ill patients
  publication-title: Clin Ther
– volume: 194
  start-page: 681
  issue: 6
  year: 2016
  end-page: 691
  article-title: Continuous versus intermittent beta‐lactam infusion in severe sepsis. A meta‐analysis of individual patient data from randomized trials
  publication-title: Am J Respir Crit Care Med
– volume: 56
  start-page: 236
  issue: 2
  year: 2013
  end-page: 244
  article-title: Continuous infusion of beta‐lactam antibiotics in severe sepsis: A multicenter double‐blind, randomized controlled trial
  publication-title: Clin Infect Dis
– volume: 58
  start-page: 1072
  issue: 8
  year: 2014
  end-page: 1083
  article-title: DALI: defining antibiotic levels in intensive care unit patients: are current beta‐lactam antibiotic doses sufficient for critically ill patients?
  publication-title: Clin Infect Dis
– volume: 59
  start-page: 905
  issue: 6
  year: 2014
  end-page: 907
  article-title: Impact of loading doses on the time to adequate predicted beta‐lactam concentrations in prolonged and continuous infusion dosing schemes
  publication-title: Clin Infect Dis
– volume: 17
  start-page: 497
  issue: 6
  year: 2001
  end-page: 504
  article-title: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia
  publication-title: Int J Antimicrob Agents
– volume: 29
  start-page: 2433
  issue: 11
  year: 2007
  end-page: 2439
  article-title: Comparison of clinical cure rates in adults with ventilator‐associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open‐label, historical chart review
  publication-title: Clin Ther
– volume: 80
  start-page: 1302
  issue: 12
  year: 2014
  end-page: 1309
  article-title: Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis
  publication-title: Minerva Anestesiol
– volume: 71
  start-page: 196
  issue: 1
  year: 2016
  end-page: 207
  article-title: Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining antibiotic Levels in intensive care unit patients (DALI) cohort
  publication-title: J Antimicrob Chemother
– volume: 59
  start-page: 285
  issue: 2
  year: 2007
  end-page: 291
  article-title: Is continuous infusion ceftriaxone better than once‐a‐day dosing in intensive care? A randomized controlled pilot study
  publication-title: J Antimicrob Chemother
– volume: 16
  start-page: R113
  issue: 3
  year: 2012
  article-title: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open‐label controlled trial
  publication-title: Crit Care
– volume: 40
  start-page: 219
  issue: 2
  year: 2006
  end-page: 223
  article-title: Meropenem by continuous versus intermittent infusion in ventilator‐associated pneumonia due to gram‐negative bacilli
  publication-title: Ann Pharmacother
– volume: 33
  start-page: 290
  issue: 3
  year: 2009
  end-page: 291
  article-title: Experience with extended‐infusion meropenem in the management of ventilator‐associated pneumonia due to multidrug‐resistant Acinetobacter baumannii
  publication-title: Int J Antimicrob Agents
– volume: 66
  start-page: ii25
  issue: Supplement 2
  year: 2011
  end-page: ii31
  article-title: Antibiotic dosing in critical illness
  publication-title: J Antimicrob Chemother
– volume: 43
  start-page: 304
  issue: 3
  year: 2017
  end-page: 377
  article-title: Surviving sepsis campaign: international Guidelines for Management of Sepsis and Septic Shock: 2016
  publication-title: Intensive Care Med
– volume: 36
  start-page: 459
  issue: 3
  year: 2017
  end-page: 466
  article-title: Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital‐acquired pneumonia: a randomized controlled trial
  publication-title: Eur J Clin Microbiol Infect Dis
– volume: 14
  start-page: 390
  issue: 4
  year: 2008
  end-page: 396
  article-title: Better outcomes through continuous infusion of time‐dependent antibiotics to critically ill patients?
  publication-title: Curr Opin Crit Care
– volume: 33
  start-page: 1022
  issue: 10
  year: 2013
  end-page: 1034
  article-title: Correlation of pharmacokinetic/pharmacodynamic‐derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia
  publication-title: Pharmacotherapy
– volume: 43
  start-page: 360
  issue: 8
  year: 2005
  end-page: 369
  article-title: Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen
  publication-title: Int J Clin Pharmacol Ther
– volume: 26
  start-page: 1
  issue: 1
  year: 1998
  end-page: 10
  article-title: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
  publication-title: Clin Infect Dis
– volume: 7
  issue: 11
  year: 2012
  article-title: Continuous infusion of piperacillin/tazobactam in septic critically ill patients—a multicenter propensity matched analysis
  publication-title: PLoS One
– volume: 35
  start-page: 763
  issue: 8
  year: 2020
  end-page: 771
  article-title: Evaluation of meropenem extended versus intermittent infusion dosing protocol in critically ill patients
  publication-title: J Intensive Care Med
– volume: 51
  start-page: 3304
  issue: 9
  year: 2007
  end-page: 3310
  article-title: Population pharmacokinetics and pharmacodynamics of continuous versus short‐term infusion of imipenem‐cilastatin in critically ill patients in a randomized, controlled trial
  publication-title: Antimicrob Agents Chemother
– volume: 192
  start-page: 1298
  issue: 11
  year: 2015
  end-page: 1305
  article-title: A multicenter randomized trial of continuous versus intermittent β‐lactam infusion in severe sepsis
  publication-title: Am J Respir Crit Care Med
– volume: 50
  start-page: 184
  issue: 2
  year: 2000
  end-page: 191
  article-title: Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis
  publication-title: Br J Clin Pharmacol
– volume: 59
  start-page: 1237
  issue: 10
  year: 2020
  end-page: 1250
  article-title: Prolonged Versus Intermittent Infusion of β‐Lactam Antibiotics: A Systematic Review and Meta‐Regression of Bacterial Killing in Preclinical Infection Models
  publication-title: Clin Pharmacokinetics
– volume: 130
  start-page: 1139
  issue: 10
  year: 2017
  end-page: 1145
  article-title: Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: A prospective randomized pilot study
  publication-title: Chin Med J (Engl)
– volume: 44
  start-page: 357
  issue: 3
  year: 2007
  end-page: 363
  article-title: Piperacillin‐tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended‐infusion dosing strategy
  publication-title: Clin Infect Dis
– volume: 44
  start-page: 358
  issue: 4
  year: 2014
  end-page: 362
  article-title: Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5‐h and 3‐h infusions
  publication-title: Int J Antimicrob Agents
– volume: 27
  start-page: 1785
  issue: 6
  year: 2018
  end-page: 1805
  article-title: Optimally estimating the sample mean from the sample size, median, mid‐range, and/or mid‐quartile range
  publication-title: Stat Methods Med Res
– volume: 42
  start-page: 1535
  issue: 10
  year: 2016
  end-page: 1545
  article-title: Beta‐Lactam Infusion in Severe Sepsis (BLISS): a prospective, two‐centre, open‐labelled randomised controlled trial of continuous versus intermittent beta‐lactam infusion in critically ill patients with severe sepsis
  publication-title: Intensive Care Med
– volume: 26
  start-page: 644
  issue: 9
  year: 2014
  end-page: 649
  article-title: Comparison of 3‐hour and 30‐minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial
  publication-title: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
– volume: 14
  start-page: 135
  year: 2014
  article-title: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
  publication-title: BMC Med Res Methodol
– volume: 58
  start-page: 4470
  issue: 8
  year: 2014
  end-page: 4475
  article-title: Extended‐infusion versus standard‐infusion piperacillin‐tazobactam for sepsis syndromes at a tertiary medical center
  publication-title: Antimicrob Agents Chemother
– volume: 47
  start-page: 483
  issue: 5
  year: 1999
  end-page: 485
  article-title: Continuous versus intermittent cefepime infusion in critical care. Preliminary results
  publication-title: Pathol Biol (Paris)
– volume: 28
  start-page: 122
  issue: 2
  year: 2006
  end-page: 127
  article-title: Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients
  publication-title: Int J Antimicrob Agents
– volume: 35
  start-page: 156
  issue: 2
  year: 2010
  end-page: 163
  article-title: First‐dose and steady‐state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis
  publication-title: Int J Antimicrob Agents
– volume: 47
  start-page: 999
  issue: 7–8
  year: 2013
  end-page: 1006
  article-title: Standard versus prolonged doripenem infusion for treatment of gram‐negative infections
  publication-title: Ann Pharmacother
– volume: 2
  start-page: 554
  issue: 6
  year: 1983
  end-page: 558
  article-title: Treatment of gram‐negative bacillary septicemia with cefoperazone
  publication-title: Eur J Clin Microbiol
– volume: 33
  start-page: 134
  issue: 2
  year: 2018
  end-page: 141
  article-title: Hospital length of stay among patients receiving intermittent versus prolonged piperacillin/tazobactam infusion in the intensive care units
  publication-title: J Intensive Care Med
– ident: e_1_2_6_13_1
  doi: 10.1186/cc11405
– ident: e_1_2_6_4_1
  doi: 10.1097/MCC.0b013e3283021b3a
– volume: 43
  start-page: 360
  issue: 8
  year: 2005
  ident: e_1_2_6_17_1
  article-title: Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen
  publication-title: Int J Clin Pharmacol Ther
  doi: 10.5414/CPP43360
– ident: e_1_2_6_10_1
  doi: 10.1177/0885066618784264
– volume: 2
  start-page: 554
  issue: 6
  year: 1983
  ident: e_1_2_6_29_1
  article-title: Treatment of gram‐negative bacillary septicemia with cefoperazone
  publication-title: Eur J Clin Microbiol
  doi: 10.1007/BF02016564
– volume: 47
  start-page: 483
  issue: 5
  year: 1999
  ident: e_1_2_6_37_1
  article-title: Continuous versus intermittent cefepime infusion in critical care. Preliminary results
  publication-title: Pathol Biol (Paris)
– ident: e_1_2_6_12_1
  doi: 10.1007/s10096-016-2819-1
– ident: e_1_2_6_5_1
  doi: 10.1164/rccm.201601-0024OC
– ident: e_1_2_6_15_1
  doi: 10.1164/rccm.201505-0857OC
– ident: e_1_2_6_21_1
  doi: 10.1093/jac/dkl478
– ident: e_1_2_6_26_1
  doi: 10.1111/j.1365-2125.2000.00179.x
– volume: 39
  start-page: 10
  year: 2011
  ident: e_1_2_6_11_1
  article-title: Prolonged vs. intermittent infusion of meropenem, piperacillin‐tazobactam, and cefepime for the treatment of life threatening gram‐negative infections in the intensive care unit
  publication-title: Crit Care Med
– ident: e_1_2_6_20_1
  doi: 10.1016/S0924-8579(01)00329-6
– volume: 80
  start-page: 1302
  issue: 12
  year: 2014
  ident: e_1_2_6_38_1
  article-title: Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis
  publication-title: Minerva Anestesiol
– ident: e_1_2_6_35_1
  doi: 10.1128/AAC.01318-06
– ident: e_1_2_6_9_1
  doi: 10.1007/s00134-015-4188-0
– ident: e_1_2_6_2_1
  doi: 10.1086/516284
– volume: 26
  start-page: 644
  issue: 9
  year: 2014
  ident: e_1_2_6_22_1
  article-title: Comparison of 3‐hour and 30‐minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial
  publication-title: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
– ident: e_1_2_6_33_1
  doi: 10.1016/j.ijantimicag.2006.02.020
– ident: e_1_2_6_16_1
  doi: 10.1093/cid/cis856
– ident: e_1_2_6_39_1
  doi: 10.1007/s00134-017-4683-6
– ident: e_1_2_6_32_1
  doi: 10.1086/510590
– ident: e_1_2_6_3_1
  doi: 10.1093/cid/ciu027
– ident: e_1_2_6_7_1
  doi: 10.1186/1471-2288-14-135
– volume: 44
  start-page: 358
  issue: 4
  year: 2014
  ident: e_1_2_6_31_1
  article-title: Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5‐h and 3‐h infusions
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2014.05.011
– ident: e_1_2_6_41_1
  doi: 10.1093/jac/dkq516
– ident: e_1_2_6_34_1
  doi: 10.1016/j.ijantimicag.2009.10.008
– volume: 59
  start-page: 905
  issue: 6
  year: 2014
  ident: e_1_2_6_40_1
  article-title: Impact of loading doses on the time to adequate predicted beta‐lactam concentrations in prolonged and continuous infusion dosing schemes
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu402
– ident: e_1_2_6_24_1
  doi: 10.1345/aph.1G467
– ident: e_1_2_6_25_1
  doi: 10.1016/j.ijantimicag.2008.09.012
– ident: e_1_2_6_36_1
  doi: 10.1177/0885066617708756
– ident: e_1_2_6_14_1
  doi: 10.1128/AAC.02759-14
– volume: 29
  start-page: 2433
  issue: 11
  year: 2007
  ident: e_1_2_6_19_1
  article-title: Comparison of clinical cure rates in adults with ventilator‐associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open‐label, historical chart review
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2007.11.003
– ident: e_1_2_6_30_1
  doi: 10.1016/j.clinthera.2012.11.005
– ident: e_1_2_6_6_1
  doi: 10.1177/0962280216669183
– ident: e_1_2_6_18_1
  doi: 10.1345/aph.1S032
– volume: 71
  start-page: 196
  issue: 1
  year: 2016
  ident: e_1_2_6_8_1
  article-title: Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining antibiotic Levels in intensive care unit patients (DALI) cohort
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkv288
– ident: e_1_2_6_23_1
  doi: 10.4103/0366-6999.205859
– ident: e_1_2_6_27_1
  doi: 10.1002/phar.1875
– volume: 7
  start-page: e49845
  issue: 11
  year: 2012
  ident: e_1_2_6_28_1
  article-title: Continuous infusion of piperacillin/tazobactam in septic critically ill patients—a multicenter propensity matched analysis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0049845
– volume: 59
  start-page: 1237
  issue: 10
  year: 2020
  ident: e_1_2_6_43_1
  article-title: Prolonged Versus Intermittent Infusion of β‐Lactam Antibiotics: A Systematic Review and Meta‐Regression of Bacterial Killing in Preclinical Infection Models
  publication-title: Clin Pharmacokinetics
  doi: 10.1007/s40262-020-00919-6
– ident: e_1_2_6_42_1
  doi: 10.1002/phar.1310
SSID ssj0006723
Score 2.367286
Snippet What is known and objective The role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains...
The role of continuous/extended beta-lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains controversial. Therefore, we...
What is known and objectiveThe role of continuous/extended beta‐lactam infusions (CEIs) in improving clinical outcomes among critically ill patients remains...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 424
SubjectTerms antibiotics
Clinical outcomes
Clinical trials
Drug therapy
infectious diseases
loading dose
Meta-analysis
Mortality
Patients
pharmacokinetics
Sepsis
Septic shock
Title Loading dose and efficacy of continuous or extended infusion of beta‐lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta‐analysis and meta‐regression analysis
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjcpt.13301
https://www.ncbi.nlm.nih.gov/pubmed/33135261
https://www.proquest.com/docview/2501873292
https://www.proquest.com/docview/2456856306
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhp176fmybhiktgZZ48UN-qOQSQkMIbVnKBnIpRpLlELqxw9o-pKf-hP673PNLOiPL3m5bCu1pzWpk2WhGmhl_-oaxV0KHvsqE8QznnAIU4QlfCy-IMwq40DRLykN--JgcnfDj0_h0g-0NZ2F6fogx4UaWYddrMnCpmp-NXF-2U4yw7OEtAmuRR_RpxR2VpLa2G8YYwuO4SztuUgvjGbuu70a_uZjrHqvdcg7vsM_Dw_ZIky_TrlVT_fUXHsf_fZu77LbzRWG_V557bMNU99nOrCezvtqF-epsVrMLOzBb0VxfPWDX72uLv4eibgzIqgBDdBTYE-oSCAJ_XnV110C9hCHVDqjPHeXnSESZVt58-76QupUXDQxoeKDUMBCNBXENYL8W5BrDL7aBo4NtemHt6jXA-WJBS7dp3sI-NJ2yZ1bgoh9IOv4V-6zuv6U564HAFQzND9nJ4bv5wZHnykR4OorTwItC3G8ypbNIoq-jsoCrVKPbazB0Urw0caJSbDM-vib-JDwojIqVSlSR8SIoo0dss6or84RBqRPhZ8oIdCq5lKEsi7RED0v6pZFCmAl7PahLrh2HOpXyWORjLIXzmNt5nLCXo-xlzxzyR6mtQetyt3o0eUgsi2kUinDCXozNaPf0MUdWBucupw_WGZG7JRP2uNfWcZgoCqjsAd78jdW5v4yfHx_M5vbq6b8IP2O3QgL3WAjTFttsl515jt5Zq7atFf4Amko_5Q
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQOcCF92OhwCBQJVCzysN5mFtVUS1lW63QVuotsh0HVWyTapMcyomfwL_jzi9hxvFmWUBIcNpoPY4TecaemXz-hrGXQoe-yoTxDOecAhThCV8LL4gzCrjQNEvKQx4dJ5MTfnganzpsDp2F6fkhhoQbWYZdr8nAKSH9s5Xri3aMIRad3rpKJb1tRPVhzR6VpLa6G0YZwuO4Tzt2UgvkGfpu7ke_OZmbPqvddA5u9pVVG8tVSFiTT-OuVWP9-Rcmx_9-n1vshnNHYa_Xn9vsiqnusJ1Zz2d9uQvz9fGsZhd2YLZmur68y75NawvBh6JuDMiqAEOMFNgT6hIIBX9WdXXXQL2EVbYdUKU7StGRiDKt_P7l60LqVp43sALEA2WHgZgsiG4A-7UgN0h-sQ0cI2zTC2tXsgHOFgtavU3zBvag6ZQ9tgLn_UDSUbDYZ3X_Lc3HHgtcwar5Hjs5eDvfn3iuUoSnozgNvCjELSdTOoskujsqC7hKNXq-BqMnxUsTJyrFNuPja-JPwoPCqFipRBUZL4Iyus-2qroyDxmUOhF-poxAv5JLGcqySEt0sqRfGimEGbFXK33JtaNRp2oei3wIp3AeczuPI_ZikL3oyUP-KLW9UrvcLSBNHhLRYhqFIhyx50Mzmj59z5GVwbnL6Zt1RvxuyYg96NV1GCaKAqp8gDd_bZXuL-Pnh_uzub169C_Cz9i1yfxomk_fHb9_zK6HhPWxiKZtttUuO_MEnbVWPbUm-QNKbkQA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIiEuvB8LBQaBKoGaVR7Ow4hL1bIqpVQrtJV6QZHtOKhim6w2yaGc-An8O-78Emacx7KAkOCUKB7Htjxjz4zH3zD2TGjfVYkwjuGck4EiHOFq4XhhQgYXimZOfsh3x9HBCT88DU832Kv-LkyLDzE43Egy7HpNAr7I8p-FXC_qMVpYdHnrEo_chHh6__0KPCqKbXI3NDKEw3Gb7sBJbRzPUHd9O_pNx1xXWe2eM7nGPvS9bUNNPo2bWo3151-AHP93ONfZ1U4Zhd2We26wDVPcZNvTFs36Ygdmq8tZ1Q5sw3SFc31xi307Km0APmRlZUAWGRjCo8CaUOZAMfBnRVM2FZRL6H3tgAzdkIOOSJSp5fcvX-dS1_K8gj4cHsg3DIRjQWADWK8GuQbxi2XQ4cFWLbHuEjbA2XxOa7epXsIuVI2yl1bgvG1IdgAstq_dt6X52EYCF9AX32Ynk9ezvQOnyxPh6CCMPSfwccNJlE4CicqOSjyuYo16r0HbSfHchJGKscy4OEx8RNzLjAqVilSW8MzLgztssygLc49BriPhJsoI1Cq5lL7MszhHFUu6uZFCmBF73rNLqjsQdcrlMU8HYwrnMbXzOGJPB9pFCx3yR6qtnuvSbvmoUp9gFuPAF_6IPRmKUfDpNEcWBucupRPrhNDdohG723Lr0EwQeJT3AH_-wvLcX9pPD_emM_t2_1-IH7PL0_1JevTm-O0DdsWnQB8bzrTFNutlYx6iplarR1YgfwCJOUK4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Loading+dose+and+efficacy+of+continuous+or+extended+infusion+of+beta%E2%80%90lactams+compared+with+intermittent+administration+in+patients+with+critical+illnesses%3A+A+subgroup+meta%E2%80%90analysis+and+meta%E2%80%90regression+analysis&rft.jtitle=Journal+of+clinical+pharmacy+and+therapeutics&rft.au=Wu%2C+Chih%E2%80%90Chien&rft.au=Su%2C+Yi%E2%80%90Chia&rft.au=Wu%2C+Kuan%E2%80%90Sheng&rft.au=Wu%2C+Tung%E2%80%90Ho&rft.date=2021-04-01&rft.issn=0269-4727&rft.eissn=1365-2710&rft.volume=46&rft.issue=2&rft.spage=424&rft.epage=432&rft_id=info:doi/10.1111%2Fjcpt.13301&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_jcpt_13301
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-4727&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-4727&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-4727&client=summon